On September 24, 2015 Nerviano Medical Sciences and Servier together reported the start of a first in Human clinical trial of the drug S 81694 (NMS-P153), an inhibitor of the mitotic checkpoint kinase MPS1 discovered by Nerviano Medical Sciences and thereafter acquired and further developed by Servier (Press release, Nerviano Medical Sciences, SEP 24, 2015, View Source [SID1234522435]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study is an open-label, non-randomized, multicenter international trial in patients with advanced or metastatic solid tumors who have failed previous therapies. An initial dose-escalation stage will be followed by expansion in specific solid tumors. The study is designed to confirm the safety and pharmacokinetics of S 81694, administered as a single agent. Secondary objectives include initial assessment of efficacy and determination of the recommended dose for phase 2.
Servier is the sponsor of the study, which is being conducted in Belgium and The Netherlands by Nerviano’s clinical affiliate Clioss. S 81694 is supplied by Nerpharma, the CMO affiliate of Nerviano.
Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: "We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) is a novel potent inhibitor of MPS1. MPS1 represents an original target overexpressed during the M phase in many types of cancers. S 81694 is highly selective for MPS1 and a brief exposure to S 81694 is sufficient to commit cancer cells to death".
Emmanuel Canet, M.D., PhD, President of Servier R&D stressed that "With the entry in clinical phase of this new antitumoral compound, Servier is reinforcing its commitment to provide innovative therapeutic solutions for unmet needs in patients with serious illnesses".
Arturo Galvani, Ph.D., Director of Drug Discovery at Nerviano Medical Sciences commented: "we have been working together with Servier, a company engaged in cutting-edge research in oncology, in an outstanding collaboration to successfully advance S81694 to clinical development and hope that this first step will further translate into clinical benefit for patients with cancer".
About MPS1:
MPS1 (also known as TTK) is a conserved kinase which is highly expressed in a number of human tumors of different origin. MPS1 plays a critical role in the control of a stage of the cell division cycle known as mitosis. During mitosis, MPS1 is involved in regulation of the spindle assembly checkpoint, a mechanism required for chromosome alignment and segregation. The activity of this checkpoint has been shown to be up-regulated in aneuploid tumors, comprising approximately 90% of solid and 70% of hematological cancers. In accelerating mitosis, MPS1 inhibitors have a novel mode of action as compared to currently available drugs targeting this stage of cell division.